About Embark Biotech
Embark Biotech is a company based in Copenhagen (Denmark) founded in 2017 by Thue Schwartz was acquired by Novo Nordisk in August 2023. The company has 3 employees as of December 31, 2021. Embark Biotech operates in a competitive market with competitors including Adocia, Altimmune, Carmot, BioAge Labs and Fractyl, among others.
- Headquarter Copenhagen, Denmark
- Employees 3 as on 31 Dec, 2021
- Founders Thue Schwartz
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Embark Biotech Aps
-
Annual Revenue
Not available
-
Net Profit
$488.07 K (USD)-78as on Dec 31, 2020
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
3
as on Dec 31, 2021
-
Acquired by
Novo Nordisk
(Aug 28, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Embark Biotech
Detailed funding history for Embark Biotech
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Embark Biotech
Embark Biotech has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Novo Nordisk.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured.
|
Locked | Locked | Locked |
Investor details for Embark Biotech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Embark Biotech
Investment portfolio details for Embark Biotech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Embark Biotech
Detailed financials for Embark Biotech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Embark Biotech Comparisons
Peer comparison for Embark Biotech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Embark Biotech
Embark Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adocia, Altimmune, Carmot, BioAge Labs and Fractyl, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| Locked | Locked | Locked |
Disease-modifying therapies for metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Bioinformatics platform is provided for biomarkers and drug discovery.
|
|
| Locked | Locked | Locked |
Endoscopic procedures for type-2 diabetes treatment are developed.
|
|
| Locked | Locked | Locked |
Peptide-based therapies for obesity and cardiometabolic disorders are developed.
|
Detailed competitors of Embark Biotech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Embark Biotech
Complete news archive for Embark Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Embark Biotech
Embark Biotech was founded in 2017.
Embark Biotech is headquartered in Copenhagen, Denmark.
As of Dec 31, 2021, the latest employee count at Embark Biotech is 3.
Embark Biotech was founded in 2017 in Copenhagen, Denmark, within the biotechnology sector. Focus is placed on developing therapeutics to address metabolic diseases and obesity. Operations center on innovative products, including EMB1, a peptide targeted at hyperphagia, and EMB2, a small molecule designed for obesity treatment. Research and development activities are conducted to advance these solutions for clinical applications.
Embark Biotech's top competitors include Adocia, BioAge Labs and Fractyl.
Embark Biotech has 1 investor. Key investors include Novo Nordisk.